BridgeBio Pharma, Inc.
BBIO
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 cliniā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$74.26
Price+7.07%
$4.90
1Y
Price
Market Cap
$14.396b
Large
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financial Reports
Key metrics over the past few years and other important metrics. Amounts in USD.-116.9%
EBITDA Margin-127.9%
Net Profit Margin-39.5%
Free Cash Flow Margin-116.9%
EBITDA Margin-127.9%
Net Profit Margin-39.5%
Free Cash Flow MarginRevenue
$502.078m
+126.3%
1y CAGR+774.5%
3y CAGR+583.7%
5y CAGREarnings
-$729.306m
-36.1%
1y CAGR-17.7%
3y CAGR-9.7%
5y CAGREPS
-$3.79
-31.6%
1y CAGR-7.5%
3y CAGR-2.1%
5y CAGRBook Value
-$2.077b
$936.025m
Assets$3.013b
Liabilities$2.729b
DebtDebt to Assets
291.5%
-4.4x
Debt to EBITDAFree Cash Flow
-$447.007m
+12.3%
1y CAGR-3.5%
3y CAGR+2.9%
5y CAGRNo items found.
Press Releases
Statements and updates from the company